blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3886824

EP3886824 - COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  19.01.2024
Database last updated on 31.08.2024
FormerRequest for examination was made
Status updated on  03.09.2021
FormerThe international publication has been made
Status updated on  06.06.2020
Formerunknown
Status updated on  17.01.2020
Most recent event   Tooltip20.06.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Fondazione Centro San Raffaele
Via Olgettina, 60
20132 Milano / IT
[2021/40]
Inventor(s)01 / CORTI, Angelo
Via Olgettina 60
20132 Milano (MI) / IT
02 / FERRERI, Andrés José Maria
Via Olgettina 60
20132 Milano (MI) / IT
 [2021/40]
Representative(s)Pace Napoleone, Maria, et al
De Simone & Partners S.r.l.
Via Vincenzo Bellini, 20
00198 Roma / IT
[N/P]
Former [2021/40]Turri, Elisa, et al
De Simone & Partners S.r.l.
Via Vincenzo Bellini, 20
00198 Roma / IT
Application number, filing date19832570.602.12.2019
[2021/40]
WO2019EP83322
Priority number, dateUS201862773473P30.11.2018         Original published format: US 201862773473 P
[2021/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020109625
Date:04.06.2020
Language:EN
[2020/23]
Type: A1 Application with search report 
No.:EP3886824
Date:06.10.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 04.06.2020 takes the place of the publication of the European patent application.
[2021/40]
Search report(s)International search report - published on:EP04.06.2020
ClassificationIPC:A61K31/00, A61K38/19, A61K39/395, A61P35/00
[2021/40]
CPC:
A61K38/191 (EP,IL,US); A61K31/475 (EP,IL,US); A61K31/573 (EP,IL,US);
A61K31/675 (EP,IL,US); A61K31/704 (EP,IL,US); A61K39/3955 (EP,IL,US);
A61P35/00 (EP,IL,US); A61K2039/505 (EP,IL,US); A61K2039/545 (EP,IL,US);
A61K2300/00 (IL); C07K2317/515 (EP,IL); C07K2317/53 (EP,IL) (-)
C-Set:
A61K31/475, A61K2300/00 (EP);
A61K31/573, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP);
A61K38/191, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/40]
TitleGerman:KOMBINIERTE BEHANDLUNG VON PRIMÄREM LYMPHOM DES ZENTRALNERVENSYSTEMS[2021/40]
English:COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA[2021/40]
French:TRAITEMENT COMBINÉ DU LYMPHOME PRIMAIRE DU SYSTÈME NERVEUX CENTRAL[2021/40]
Entry into regional phase21.06.2021National basic fee paid 
21.06.2021Designation fee(s) paid 
21.06.2021Examination fee paid 
Examination procedure21.06.2021Examination requested  [2021/40]
21.06.2021Date on which the examining division has become responsible
14.01.2022Amendment by applicant (claims and/or description)
22.01.2024Despatch of a communication from the examining division (Time limit: M06)
20.06.2024Reply to a communication from the examining division
Fees paidRenewal fee
18.11.2021Renewal fee patent year 03
21.12.2022Renewal fee patent year 04
27.12.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]AU2008207357  (BIOGEN IDEC INC) [Y] 1-7 * pages 23,30 *;
 [Y]EP2364995  (MOLMED SPA [IT], et al) [Y] 1-7* paragraphs [0012] , [0019] - [0022] - [0199] , [0205] *;
 [Y]US2015246123  (DOSHI PARUL [US]) [Y] 1-7 * paragraphs [0013] - [0018] *;
 [XY]  - FERRERI ANDRES J M ET AL, "R-CHOP Preceded By Engineered Tumor Necrosis Factor (TNF) in Patients with Relapsed or Refractory (r/r) Primary CNS Lymphoma (PCNSL): Results of Antitumor Activity, Safety and Blood-Brain Barrier (BBB) Permeabilization in the "Ingrid" Phase II Trial", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20181129), Database accession no. PREV201900317358, XP002798112 [X] 1,3-5,7 * abstract * [Y] 1-7

DOI:   http://dx.doi.org/10.1182/blood-2018-99-118507
    [ ] - BLOOD, 60TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); SAN DIEGO, CA, USA; DECEMBER 01 -04, 2018, (20181129), vol. 132, no. Suppl. 1, doi:10.1182/BLOOD-2018-99-118507, ISSN 0006-4971(print), page 1687
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.